Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Trial Details

NCT ID
NCT05315700
Phase
PHASE1 / PHASE2
Sponsor
ORIC Pharmaceuticals
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • ORIC-114
  • Chemotherapy drug
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Huntington Beach, California, United States|33.6603,-117.99923
  • Irvine, California, United States|33.66946,-117.82311
  • Long Beach, California, United States|33.76696,-118.18923
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation or a…
  • Part I Dose Escalation (CLOSED) Any solid tumor with
  • EGFR exon 20 insertion mutation
  • HER2 exon 20 insertion mutation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →